-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 8, senior executives of nine major pharmaceutical companies in the U.S. and Europe issued a rare joint statement saying they would not apply for approval from the relevant authorities until the vaccine had passed phase III clinical trials and was proven to be safe and effective, the U.S. daily reported.
said the move would help boost public confidence in the vaccine.
"We believe this statement will help ensure public trust in rigorous scientific and regulatory processes in which the new crown vaccine will be evaluated and may eventually be approved," nine pharmaceutical executives reportedly wrote in a joint statement.
executives also vowed to "apply for approval or emergency use permits only after Phase III clinical trials have confirmed that the vaccine is safe and effective, and that the trials were designed and implemented to meet the conditions set by professional authorities such as the U.S. Food and Drug Administration."
they also vowed to "always put the safety and health of vaccinators first."
said in the "historic statement" that the companies would "maintain the integrity of the scientific process when it is possible to apply to global authorities for approval for the first new crown vaccine at a later time,"
reported.
The statement also does not rule out the use of some data from large-scale Phase III vaccine trials to apply for emergency use permits;
said the drug company executives who signed the statement were Pfizer, Johnson and Johnson, Moderna, Novavax, GlaxoSmithKline, AstraZeneca, Merck, BioNTech and Sanofi, France.
comes after the U.S. Centers for Disease Control and Prevention (CDC) asked states to have the equipment they need to distribute vaccines by November 1.
, U.S. infectious disease expert Fuchs said on September 8th that the new vaccine may not be available before the U.S. election.
said at a conference that vaccines were more likely to be successful by the end of the year, but that "there can be no decisive answer" until November 3.
U.S. President Donald Trump said at a news conference Wednesday that the vaccine is expected to be distributed before polling day in the U.S. election.
U.S. infectious disease experts and scientists are concerned that the vaccine approval process could be "politically" affected.
.